5 Key Takeaways

• 1

  The US Supreme Court ruled that the President cannot impose tariffs under the International Emergency Economic Powers Act, complicating compliance for pharma companies.

• 2

  Pharmaceutical companies face rising costs and delays in clinical trials due to geopolitical tensions and existing tariffs, impacting their operational strategies.

• 3

  Organizations must conduct granular audits to assess the impact of overturned tariffs and existing duties, while seeking exemptions to mitigate financial losses.

• 4

  Companies are reevaluating their manufacturing locations and clinical trial plans due to policy volatility and uncertain cost forecasts.

• 5

  The ongoing conflict in the Middle East is expected to increase costs and supply shortages across the pharmaceutical industry, affecting logistics and planning.